What is the Eldon (Eledon) clinical trial investigating, who is eligible (adults with type 1 diabetes eligible for pancreatic islet transplantation), what investigational immunosuppressive regimen (anti‑CD40L antibody tegoprubart) is used, and what have been the outcomes to date?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tegoprubart in Islet Transplantation for Type 1 Diabetes

Tegoprubart (AT-1501) is an anti-CD40L monoclonal antibody being investigated as an immunosuppressive agent for pancreatic islet transplantation in adults with type 1 diabetes who have severe metabolic instability, hypoglycemia unawareness, or end-stage renal disease requiring kidney transplantation. 1

What Tegoprubart Is and How It Works

Tegoprubart is an engineered anti-CD40 ligand (CD40L) antibody specifically designed to prevent the thromboembolic complications that plagued earlier anti-CD40L antibodies. The engineering reduced binding to Fcγ receptors on platelets while preserving the critical CD40L blockade needed for immunosuppression 1. This costimulatory blockade prevents T-cell and B-cell activation, which is essential for preventing both allograft rejection and potentially the autoimmune destruction of transplanted islets.

Clinical Trial Evidence and Outcomes

Preclinical Success

In nonhuman primate models, tegoprubart demonstrated remarkable efficacy:

  • As monotherapy, it achieved long-term survival of both intrahepatic islet allografts (cynomolgus macaques) and kidney allografts (rhesus macaques) 1
  • Compared to conventional immunosuppression, tegoprubart-treated animals showed higher C-peptide levels, better weight gain, and reduced cytomegalovirus reactivation 1
  • These results provided strong justification for human trials

Current Clinical Development

Tegoprubart has progressed to human trials, with safety data from a Phase 2A study in amyotrophic lateral sclerosis patients (different indication) showing it is well-tolerated with dose-dependent target engagement 2. The most common adverse events were fatigue (25.9%), falls (22.2%), headaches (20.4%), and muscle spasms (11.1%), though these may be disease-specific 2.

Recent 2026 evidence suggests tegoprubart is being considered as adjunct immunomodulation for gene-edited hypoimmune islets, indicating its continued relevance in the diabetes transplantation field 3.

Patient Eligibility Criteria

Based on ADA guidelines and clinical practice, adults eligible for islet transplantation must meet all three criteria 4:

  1. Frequent, acute, severe metabolic complications requiring medical attention (hypoglycemia, marked hyperglycemia, ketoacidosis)
  2. Incapacitating clinical and emotional problems with exogenous insulin therapy
  3. Consistent failure of insulin-based management to prevent acute complications

Additional Screening Requirements

Before enrollment, patients must undergo assessment for 5:

  • Negative C-peptide (positive C-peptide is an exclusion)
  • Adequate kidney function (creatinine and microalbuminuria assessment)
  • No liver disorders (alcohol-related or iron overload)
  • No active pregnancy plans
  • Absence of HFE heterozygosity complications

For patients with established end-stage renal disease who have had or plan kidney transplantation, islet-after-kidney transplantation is appropriate since the pancreas addition does not jeopardize patient survival and may improve kidney survival 4.

Advantages Over Conventional Immunosuppression

The tegoprubart approach offers several theoretical advantages:

  • Reduced toxicity profile compared to traditional triple immunosuppression (tacrolimus, mycophenolate mofetil, prednisolone) 6
  • Lower infection risk, particularly CMV reactivation 1
  • Better metabolic outcomes with higher C-peptide preservation 1
  • Engineered safety to avoid thromboembolic complications that ended earlier CD40L antibody development 1

Critical Limitations and Caveats

Long-Term Durability Remains Uncertain

The central unanswered question is whether short-term immune evasion translates to durable long-term graft survival 3. Even with the Edmonton protocol using conventional immunosuppression, only 44% of patients achieved insulin independence at 1 year, and 76% of those required insulin again by 2 years 7. Whether tegoprubart improves these outcomes requires longer follow-up.

Theoretical Long-Term Vulnerabilities

Several mechanisms may cause delayed graft failure 3:

  • Indirect allorecognition and non-HLA antibody formation
  • Persistent autoreactive immune memory
  • β-cell stress-induced neoantigen formation
  • Viral infection susceptibility

Practical Considerations

  • Islet transplantation should only occur at tertiary care centers with active kidney transplant programs and multidisciplinary evaluation protocols 4
  • Lifelong immunosuppression remains necessary even with tegoprubart, though the regimen may be less toxic 4, 1
  • Patient motivation and proper counseling are critical—in one series, 16 of 41 patients (39%) declined to proceed after initial information, with 6 preferring insulin pump therapy instead 5

Current Status

Tegoprubart represents a promising evolution in islet transplantation immunosuppression, with strong preclinical data supporting its safety and efficacy 1. However, it remains investigational and should only be used within controlled clinical trial settings 4. The drug has received FDA attention (based on 2026 labeling references), suggesting regulatory progress, though specific approval status for islet transplantation requires verification through active clinical trial registries.

Durable success will likely require combining tegoprubart with other strategies such as metabolic support or additional immunomodulation rather than relying on it as monotherapy 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.